Innovation in immunomodulation

ImCheck Therapeutics is driving innovation in two powerful new areas of immune system modulation: the butyrophilins superfamily of immunomodulatory molecules and gamma-delta T cells.  The company is  developing next generation immunotherapeutics for patients with severe unmet medical needs with a primary focus on immuno-oncology. Our growing understanding of these novel targets has also identified unique opportunities in immune-mediated inflammatory disease also known as autoimmune diseases.

Latest news


ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
Financial & Business 
Read more
ImCheck Therapeutics awarded €2 million from Bpifrance to advance its first-in-class immunotherapy program into the clinic
Financial & Business 
Read more
ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD, as Chief Medical Officer
Leadership & Corporate 
Read more

Upcoming events


ASH 2019

From  Dec 07, 2019  to  Dec 10, 2019 

Read more

Biofit 2019

From  Dec 10, 2019  to  Dec 11, 2019 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and news